Free Newsletter
Register for our Free Newsletters
Newsletter
Zones
Analysis, Inspection and Laboratory
LeftNav
Assisted/Independent Living
LeftNav
Clinical and Nursing Equipment
LeftNav
Design and Manufacture of Medical Equipment
LeftNav
Diagnostics Equipment, Monitoring and Test
LeftNav
Education, Training and Professional Services
LeftNav
Health Education and Patient Management
LeftNav
Health Estates Management
LeftNav
Healthcare Support and Information Services
LeftNav
Hygiene and Infection Control
LeftNav
IT and Communications in Healthcare
LeftNav
Materials
LeftNav
Medical Device Technology
LeftNav
Research and Development
LeftNav
Safety and Security
LeftNav
View All
Other Carouselweb publications
Carousel Web
Defense File
New Materials
Pro Health Zone
Pro Health Zone
Pro Security Zone
Web Lec
Pro Engineering Zone
 
 
News

Long term Endeavor drug-eluting stent safety profile data is released

Medtronic : 31 March, 2008  (New Product)
Medtronic has released data at the American College of Cardiology meeting that shows the company’s Endeavor drug-eluting stent exhibits a safety profile more commonly associated with a bare-metal stent, long considered a benchmark for stent safety.
“This latest extension to our pooled safety analysis of data from the Endeavor clinical programme nearly doubles the number of Endeavor patients followed to three years and therefore strengthens our confidence in the findings we presented previously,” explained Dr Laura Mauri, chief scientific officer of the Harvard Clinical Research Institute, an interventional cardiologist at the Brigham and Women’s Hospital (both in Boston) and the lead author of the research. “With more than 1,200 patients whose clinical follow-up now extends to three years, the Endeavor drug-eluting Stent continues to be associated with low rates of Stent thrombosis, myocardial infarction and cardiac death – three key safety metrics – compared to the Driver bare-metal stent. Importantly, there were no new Stent thrombosis events among patients in either group.”

Launched by Medtronic in the USA in February 2008, the Endeavor Stent is designed to promote rapid, complete and functional healing of the endothelium so that late safety concerns are minimised. The Stent features an advanced cobalt alloy in a modular architecture for deliverability and conformability, the antiproliferative drug zotarolimus to moderate neointimal hyperplasia, and a highly biocompatible polymer called phosphorylcholine (PC) for rapid drug elution.

The independent analysis performed by Dr Mauri and colleagues – ‘The Endeavor Zotarolimus-Eluting Stent in Patients with Native Coronary Artery Disease: Safety with 1,200 Patients Followed to Three Years’ (2900-104) – included a total of 2,132 Endeavor patients and 596 Driver patients
Bookmark and Share
 
Home I Editor's Blog I News by Zone I News by Date I News by Category I Special Reports I Directory I Events I Advertise I Submit Your News I About Us I Guides
 
   Β© 2012 ProHealthServiceZone.com
Netgains Logo